LEXINGTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that company management will present a corporate overview at the following upcoming investor conferences:
- Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 8:00 a.m. Eastern Time at the Lotte New York Palace Hotel in New York, NY
- Evercore ISI Healthcare Conference on Wednesday, November 28, 2018 at 12:50 p.m. Eastern Time at the Boston Harbor Hotel in Boston, MA
A live and archived webcast of the presentations will be accessible through the “Events and Presentations” page of the company's website at investors.translate.bio.
About Translate Bio
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The Company’s MRT platform is designed to develop product candidates that deliver mRNA carrying instructions to produce intracellular, transmembrane and secreted proteins for therapeutic benefit. Translate Bio believes that its MRT platform is applicable to a broad range of diseases caused by insufficient protein production or where production of proteins can modify disease, including diseases that affect the lung, liver, eye, central nervous system, lymphatic system and circulatory system. The Company also believes its platform may be applied to produce therapeutic antibodies and vaccines in areas such as infectious disease and oncology. Translate Bio’s two lead programs are being developed as treatments for cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency. For more information about the Company, please visit www.translate.bio or on Twitter at @TranslateBio.
Contacts for Translate Bio
Source: Translate Bio, Inc.